Maintaining Weight Loss With GLP-1 Tablets After Injectable Treatment - Guide | Cured Pharmacy

Maintaining Weight Loss With GLP-1 Tablets After Injectable Treatment

Weight Loss

Featured Product

Weight Loss

UK-based prescribers · Discreet delivery · Free private prescription
Start Assessment →✓ Lowest price guarantee
DISCOUNT CODE: FIRST20

£20 off for new patients

Tarun Kumar, Prescribing Pharmacist at Cured Pharmacy

Medically reviewed by

Tarun Kumar, Prescribing Pharmacist (GPhC 2233073)

Reviewed on: 8 June 2026

Last Updated: 12 August 2026

If you have been struggling to lose weight despite eating well and exercising regularly, you are far from alone. Millions of people across the UK face the same frustrating cycle, and for many, the answer may lie in a class of medications that work with your body's own hormones rather than against them. GLP-1 receptor agonists have transformed obesity treatment in recent years, offering clinically proven results that go well beyond what diet and exercise alone can achieve.

Quick Summary

GLP-1 medications mimic a natural gut hormone to reduce appetite, slow digestion and promote significant, sustained weight reduction. They are now available in the UK as prescription treatments for obesity and weight-related health conditions.

  • GLP-1 receptor agonists reduce appetite and food intake by acting on hunger centres in the brain
  • Clinical trials show up to 20% body weight loss with tirzepatide and up to 15% with semaglutide
  • UK-licensed options include Wegovy (semaglutide) and Mounjaro (tirzepatide)
  • Side effects are mostly gastrointestinal and tend to improve after the initial dose escalation period
  • These medicines work best when combined with a reduced-calorie diet and regular physical activity

GLP-1 Weight Loss Timeline Estimator

Enter your details below to get a personalised estimate of how much weight you could lose on a GLP-1 medication over 12 months.

What Is a GLP-1 and How Does It Drive Weight Loss?

GLP-1 stands for glucagon-like peptide-1, a hormone naturally produced in the gut after you eat. Its primary role is to signal to your brain that you are full, slow down the emptying of your stomach and stimulate the pancreas to release insulin in response to rising blood glucose. When you take a GLP-1 receptor agonist, you are essentially amplifying these signals beyond what your body produces naturally, making hunger less intense, meals more satisfying and overeating far less likely. To understand more about how this hormone functions on a biochemical level, the guide on GLP-1 meaning and what this hormone does in your body is well worth reading.

The pain point this addresses is significant. Traditional approaches to weight management — calorie restriction and increased activity — fight against the body's natural drive to restore lost energy. The brain responds to weight loss by increasing hunger hormones and reducing satiety signals, creating an almost impossible uphill battle. GLP-1 medications interrupt this cycle at a hormonal level, making it physiologically easier to eat less without the constant white-knuckle willpower that conventional dieting demands.

Research published in leading medical journals has confirmed that these drugs act not only on the gut but also on reward centres in the brain, reducing cravings for high-calorie foods. This dual action — peripheral and central — is why weight loss with GLP-1 therapy is so much more effective than earlier pharmacological approaches. Patients frequently describe a quiet reduction in food noise, meaning the persistent mental chatter about eating simply becomes quieter, sometimes within the first week of treatment.

  • GLP-1 slows gastric emptying, keeping you fuller for longer after meals
  • It acts on the hypothalamus to reduce appetite and food reward signalling
  • It improves insulin sensitivity, which supports fat metabolism
  • Natural GLP-1 is degraded rapidly in the body; receptor agonists are designed to last much longer

GLP-1 Medications Available in the UK for Weight Loss With GLP-1

Several GLP-1 receptor agonists are currently licensed or used in the UK for weight management. The two most prominent are semaglutide (sold as Wegovy for weight loss and Ozempic for type 2 diabetes) and tirzepatide (sold as Mounjaro). Liraglutide (Saxenda) was the first GLP-1 drug licensed specifically for weight management and remains available, though it has largely been superseded by the newer, more effective once-weekly options. You can explore the full range of weight loss treatments at Cured Pharmacy to find the most appropriate option for your circumstances.

Mounjaro (tirzepatide) is worth highlighting as a dual GIP and GLP-1 receptor agonist. Unlike pure GLP-1 drugs, it activates two incretin hormone pathways simultaneously, which appears to amplify its weight-loss effect considerably. Clinical trial data from the SURMOUNT programme showed average weight reductions of around 20% of body weight over 72 weeks at the highest dose, making it the most effective injectable weight loss medication currently licensed in the UK. If you want to understand tirzepatide in depth, the detailed article on Mounjaro tirzepatide KwikPen for weight loss covers everything from dosing to injection technique.

Wegovy (semaglutide 2.4 mg weekly) was approved by the MHRA and began NHS rollout in 2023, with access in 2026 continuing to expand through specialist weight management services and private prescribers. Both Mounjaro and Wegovy are administered via a simple subcutaneous injection once weekly, using a pre-filled pen device that most patients find straightforward after initial guidance from their prescriber.

  • Wegovy (semaglutide 2.4 mg weekly) — licensed for weight management
  • Mounjaro (tirzepatide up to 15 mg weekly) — dual GIP/GLP-1 agonist, highest efficacy
  • Saxenda (liraglutide 3 mg daily) — first licensed GLP-1 for weight loss, once daily injection
  • Ozempic (semaglutide, diabetes licensed but sometimes used off-label in obesity)

Who Qualifies for GLP-1 Weight Loss Treatment in the UK?

Eligibility for GLP-1 weight loss medication in the UK is guided by NICE criteria and individual prescriber assessment. For Wegovy, the general requirement is a BMI of 30 or above, or a BMI of 27 or above with at least one weight-related comorbidity such as type 2 diabetes, hypertension, dyslipidaemia, obstructive sleep apnoea or cardiovascular disease. Mounjaro has similar prescribing criteria. A detailed breakdown of BMI requirements for weight loss injections can help you understand whether you may be eligible before speaking with a prescriber.

On the NHS, access remains relatively restricted despite the 2026 rollout continuing. Most patients currently access GLP-1 medications through specialist tier 3 weight management services or through specialist NHS clinics following a referral from their GP. Private prescribing through registered online pharmacies and clinics, however, has made these treatments far more accessible for those who meet the clinical criteria but face long waiting lists on the NHS.

It is important to understand that these medications are not appropriate for everyone. They are contraindicated in pregnancy and should be used with caution in people with a personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2, pancreatitis or severe gastrointestinal disease. A thorough medical consultation is essential before starting any GLP-1 therapy, and prescribers will review your full medical history, current medications and any relevant blood tests before issuing a prescription.

  • BMI of 30 or above typically required, or 27 with a comorbidity
  • NHS access mainly via specialist weight management services
  • Private access available through registered UK prescribers and pharmacies
  • Contraindicated in pregnancy, medullary thyroid carcinoma and certain GI conditions
  • Regular clinical review is required throughout treatment

What Results Can You Realistically Expect?

One of the most common questions people ask before starting treatment is how much weight they can actually lose. The honest answer is that results vary depending on the medication, the dose reached, individual metabolism, diet quality and activity levels. That said, clinical evidence provides some clear benchmarks. The STEP 1 trial for semaglutide 2.4 mg reported an average weight loss of 14.9% of body weight over 68 weeks compared to placebo. The SURMOUNT-1 trial for tirzepatide 15 mg reported an average loss of 20.9% of body weight over 72 weeks, with some participants losing more than 25%.

In real-world UK practice, many patients report losing between 10% and 15% of their starting weight within the first year of treatment on semaglutide, and between 15% and 20% on tirzepatide. For someone starting at 110 kg, that could mean losing anywhere between 11 and 22 kg — a range that could meaningfully reduce the risk of type 2 diabetes, improve blood pressure and relieve joint pain. The article on GLP-1 weight loss results and how much you can lose explores comparative outcome data in more detail.

It is also worth understanding the timeline. Most people experience a noticeable reduction in appetite within the first two weeks, but measurable weight loss on the scales typically begins between weeks four and eight as the dose escalates. The greatest rate of weight loss usually occurs between months three and nine, after which the rate slows as the body approaches its new set point. Weight is generally maintained as long as treatment continues, but regain after stopping is well documented — which is why long-term treatment planning is an important conversation to have with your prescriber.

  • Average 15% body weight loss with semaglutide over approximately 16 months
  • Average 20% body weight loss with tirzepatide at maximum dose
  • Appetite reduction typically felt within weeks 1 to 3
  • Weight regain common after stopping — ongoing management plan is important
  • Results are significantly enhanced by dietary and lifestyle changes alongside medication

Managing Side Effects on GLP-1 Therapy

Side effects are one of the biggest concerns people have when starting a new medication, and GLP-1 drugs are no exception. The most commonly reported issues are gastrointestinal: nausea, vomiting, diarrhoea, constipation and abdominal discomfort. These tend to be most noticeable during the initial dose escalation phase and usually improve significantly once the body adapts to the medication, typically within four to eight weeks at each dose level. The guide on understanding side effects when starting GLP-1 treatment provides reassuring, practical guidance on what to expect and how to manage discomfort safely.

Nausea is by far the most frequently reported issue. It can usually be managed effectively by eating smaller portions, avoiding high-fat or heavily spiced meals, staying well hydrated and taking the injection on a consistent day of the week. Injecting in the evening means many people sleep through the worst of the nausea. More serious side effects, including acute pancreatitis and gallbladder disease, are rare but well documented, and any sudden severe abdominal pain should be assessed by a doctor promptly.

A common concern, particularly among those who are exercising alongside their treatment, is muscle loss. The worry is that rapid weight loss may break down lean tissue as well as fat. Current evidence suggests that while some lean mass loss does occur, the proportion of fat loss is significantly greater than with conventional dieting, particularly when adequate protein intake and resistance exercise are maintained. The dedicated article on whether GLP-1s like Mounjaro cause muscle loss addresses this concern with clinical evidence.

  • Nausea is most common — usually mild to moderate and temporary
  • Eating slowly, in smaller amounts and avoiding fatty meals reduces GI symptoms
  • Serious side effects such as pancreatitis are rare but require immediate medical attention
  • Muscle loss risk is low but minimised further by adequate protein and resistance training
  • Hair thinning (telogen effluvium) can occur with rapid weight loss — usually temporary

GLP-1 Medications Compared: A Quick Reference Table

Medication Active Ingredient Frequency Average Weight Loss UK Licensed for Weight Loss Starting Dose Maximum Dose
Wegovy Semaglutide Once weekly injection ~15% body weight Yes (MHRA approved) 0.25 mg/week 2.4 mg/week
Mounjaro Tirzepatide Once weekly injection ~20% body weight Yes (MHRA approved) 2.5 mg/week 15 mg/week
Saxenda Liraglutide Once daily injection ~8–10% body weight Yes (MHRA approved) 0.6 mg/day 3.0 mg/day
Ozempic Semaglutide Once weekly injection ~10–12% body weight No (licensed for T2DM only) 0.25 mg/week 2.0 mg/week

How to Optimise Your Lifestyle for Best GLP-1 Outcomes

GLP-1 medications are powerful, but they are not a standalone solution. The patients who achieve the best long-term results are those who use the reduced appetite as an opportunity to build genuinely healthier eating habits rather than simply eating less of the same foods. A diet rich in lean protein, vegetables, wholegrains and healthy fats supports both weight loss and the preservation of lean muscle mass. You might also find the article on what to eat on Mounjaro helpful for practical meal planning ideas during treatment.

Physical activity plays a complementary role. You do not need to undertake extreme exercise regimes, and the evidence is clear that moderate, consistent activity — brisk walking, swimming, cycling or strength training — significantly enhances the metabolic benefits of GLP-1 therapy. Building muscle through resistance exercise is particularly valuable because it raises resting metabolic rate, helping you maintain your lower weight even if medication is eventually tapered or stopped. Supplements may also be worth considering during treatment, particularly protein, vitamin B12 and vitamin D if dietary intake is reduced due to smaller meal sizes.

Sleep quality is another often-overlooked factor. Poor sleep elevates cortisol and ghrelin — the hunger hormone — which can partially counteract the appetite-suppressing effects of GLP-1 therapy. Aiming for seven to nine hours of quality sleep per night supports hormonal balance and helps the medication work more effectively. Stress management matters too: chronic psychological stress drives cortisol-mediated fat storage, particularly around the abdomen, which GLP-1 medication alone cannot fully address.

  • Prioritise protein at every meal to support lean mass during weight loss
  • Resistance training two to three times per week complements GLP-1 treatment
  • Avoid high-fat, high-sugar trigger foods that worsen GI side effects
  • Aim for seven to nine hours of sleep to support hormonal regulation
  • Consider nutritional supplements if meal sizes are significantly reduced

Long-Term Planning: Staying at a Healthy Weight After GLP-1 Treatment

One of the most common fears among people considering GLP-1 therapy is what happens when the medication stops. This is a legitimate concern. Studies published in 2022 and 2023 confirmed that a significant proportion of lost weight is regained within one to two years of stopping semaglutide, even when lifestyle interventions are maintained. This has led many clinicians in 2026 to reconsider obesity as a chronic, relapsing condition that may require long-term or even lifelong pharmacological management — much like hypertension or type 2 diabetes.

The practical implication is that your prescriber should work with you not just to initiate treatment but to develop a personalised long-term strategy. This might involve continuing medication at a maintenance dose, transitioning to a lower-intensity option, or intensifying lifestyle interventions over time to build the habits that sustain weight management independently. The article on when and how to move to a Mounjaro maintenance dose is particularly useful for those approaching their target weight and planning next steps.

For those who are not losing weight as expected, it is worth understanding that plateau periods are normal and do not necessarily mean the medication has stopped working. Reviewing diet quality, protein intake, sleep, stress and physical activity can often identify factors that are limiting progress. If these have all been addressed and weight loss remains stalled, a dose review with your prescriber may be warranted. The guide on no weight loss on Mounjaro: causes and solutions offers a structured troubleshooting approach.

  • Weight regain after stopping GLP-1 treatment is well documented — plan ahead
  • Consider obesity as a chronic condition requiring ongoing management
  • A maintenance dose strategy should be discussed with your prescriber
  • Lifestyle habits built during treatment are crucial for long-term success
  • Regular follow-up appointments help catch and address plateaus early

Key Takeaways

  • GLP-1 receptor agonists represent the most effective non-surgical weight loss tools currently available in the UK, with tirzepatide offering average losses of around 20% of body weight
  • These medications work by mimicking a natural gut hormone to reduce appetite, slow gastric emptying and improve insulin sensitivity — addressing the biological drivers of obesity rather than relying on willpower alone
  • UK-eligible patients typically require a BMI of 30 or above, or 27 with a related health condition, and treatment must be overseen by a qualified prescriber
  • Side effects are largely gastrointestinal and manageable, particularly with dietary adjustments during dose escalation; serious adverse events are rare but should be monitored
  • Long-term success requires treating obesity as a chronic condition — combining GLP-1 medication with sustainable dietary habits, regular physical activity, good sleep and ongoing clinical review

When to Seek Professional Advice

You should speak to a qualified UK prescriber or GP before starting any GLP-1 weight loss treatment, particularly if you have a history of pancreatitis, gallbladder disease, thyroid cancer, kidney disease or are currently pregnant or breastfeeding. During treatment, seek urgent medical attention if you experience severe or persistent abdominal pain, persistent vomiting that prevents you from keeping fluids down, any signs of an allergic reaction such as rash, swelling or difficulty breathing, or any sudden changes in vision or mood. Routine follow-up appointments every one to three months are strongly recommended to monitor progress, review your dose and assess any side effects. Never adjust your dose without guidance from your prescriber, and always inform any other healthcare professional you see that you are taking a GLP-1 medication, as it may affect drug absorption and the efficacy of oral contraceptives in particular.

Scientific References

  1. Wilding JPH, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. Available via NICE evidence review: NICE Technology Appraisal TA875 — Semaglutide for Weight Management [Accessed 12 August 2026]
  2. Jastreboff AM, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. Summarised in NICE guidance: NICE Technology Appraisal TA1026 — Tirzepatide for Weight Management [Accessed 12 August 2026]
  3. MHRA (2023). Wegovy (semaglutide) and Mounjaro (tirzepatide): UK licensing information and prescribing guidance. Available at: Medicines and Healthcare Products Regulatory Agency (MHRA) [Accessed 12 August 2026]
  4. Semaglutide for managing overweight and obesity (TA875), NICE Technology Appraisal, 2023 [Accessed 12 August 2026]
  5. Rybelsus 3 mg, 7 mg and 14 mg tablets (oral semaglutide) Summary of Product Characteristics, Novo Nordisk, EMC, 2023 [Accessed 12 August 2026]
  6. GLP-1 receptor agonists position statement, Diabetes UK, 2022 [Accessed 12 August 2026]
  7. Wilding JPH et al., Once-weekly semaglutide in adults with overweight or obesity (STEP 1 trial), The Lancet, 2021 [Accessed 12 August 2026]
  8. Lean MEJ & Malkova D, Altered gut and adipose tissue hormones in overweight and obese individuals: cause or consequence? BMJ, 2021 [Accessed 12 August 2026]
  9. Type 2 diabetes in adults: management (NG28), NICE guideline, updated 2022 [Accessed 12 August 2026]

Start Your Assessment For Weight Loss

Start your journey to better health today.

  • Reviewed by UK-based prescribers
  • Takes under 3 minutes
  • Discreet Packaging

Start Your Journey To Better Health Today.

Once you complete a short online assessment, you will be able to choose your preferred treatment and quantity from a list of safe, medically approved options tailored to you.

Start My AssessmentReturning Customer?Log In to Your Account

Frequently Asked Questions

How long does weight loss with GLP-1 medications take to show results?

Weight loss with GLP-1 medications typically begins within the first two to four weeks, with most people noticing meaningful changes in appetite almost immediately. Significant weight reduction, often five percent or more of body weight, is generally seen within twelve weeks, while maximum results are usually achieved over twelve to eighteen months of continued treatment.

Is weight loss with GLP-1 treatment safe for long-term use?

Weight loss with GLP-1 receptor agonists is considered safe for long-term use when prescribed and monitored by a qualified healthcare professional. Clinical trials including the STEP and SURMOUNT programmes have followed patients for up to two years with an acceptable safety profile, though regular clinical review and monitoring remain essential throughout treatment.

Can you take GLP-1 medications with other weight loss treatments?

Taking GLP-1 medications alongside other weight loss treatments such as orlistat or additional appetite suppressants is generally not recommended without specialist guidance, as combining treatments can increase the risk of side effects. Your prescriber will review your full medication list and medical history before recommending the most appropriate single treatment approach for you.

What is the dose of GLP-1 medication for weight loss in the UK?

The dose of GLP-1 medication for weight loss in the UK depends on which drug is prescribed. Semaglutide (Wegovy) is typically started at 0.25 mg weekly and increased gradually to 2.4 mg, while tirzepatide (Mounjaro) begins at 2.5 mg weekly and can be escalated to 15 mg over several months under clinical supervision.

Back to blog